Dec 15, 2017· Comment from Association for Accessible Medicines· FDA-2017-D-5974-0007
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding Docket FDA-2017-D-5974: Determining Whether to Submit an ANDA or a 505(b)(2) Application.